We are live on ! Find out more

26 hedge funds and large institutions have $270K invested in iBio in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.18% less ownership

Funds ownership: 0.34%0.16% (-0.18%)

7% less funds holding

Funds holding: 2826 (-2)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

61% less capital invested

Capital invested by funds: $696K → $270K (-$426K)

Holders
26
Holders Change
-2
Holders Change %
-7.14%
% of All Funds
0.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
5
Reduced
5
Closed
7
Calls
$116K
Puts
Net Calls
+$116K
Net Calls Change
+$40K

IBIO Hedge Fund Activity: Q3 2023 in Review

26 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q3 2023, worth a combined $270K — down 61% from $696K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of IBIO and 5 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 5 added.

The largest buyer was HRT Financial, opening a new position worth an estimated $27.5K. The largest seller was Vanguard Group, cutting an estimated $113K.

  • 26 institutional investors held iBio (IBIO) as of Q3 2023, down from 28 in Q2 2023.
  • Funds reported $270K of iBio stock for Q3 2023, down 61% quarter-over-quarter.
  • 5 funds opened new iBio positions in Q3 2023 and 7 closed out, a net change of -2 holders.
  • The largest iBio buyer in Q3 2023 was HRT Financial, an estimated $27.5K added.
  • The largest iBio seller in Q3 2023 was Vanguard Group, an estimated $113K sold.

Based on aggregated 13F filings for Q3 2023.